Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 28, 2015 11:42 AM ET

Healthcare Providers and Services

Company Overview of Memorial Sloan Kettering Cancer Center

Company Overview

Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...

1275 York Avenue

67th-68th Streets

New York, NY 10065

United States

Founded in 1884

Phone:

212-639-2000

Fax:

212-717-3299

Key Executives for Memorial Sloan Kettering Cancer Center

Chief Executive Officer and President
Age: 61
Senior Vice President of Finance
Chief Operating Officer
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2014.

Memorial Sloan Kettering Cancer Center Key Developments

Memorial Sloan Kettering Cancer Center Announces FDA Grants Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease

Memorial Sloan Kettering Cancer Center has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD), a type of malignancy occurring after allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is also commonly called a bone marrow transplant. EBV-CTL may provide an 'off-the-shelf', allogeneic, cellular therapeutic option for patients with EBV-LPD. EBV-CTL are made from T-cells collected from the blood of third-party donors. Once collected, the T-cells are exposed to certain antigens. The resulting activated T-cells are expanded, characterized and stored for future therapeutic use in an appropriate partially human leukocyte antigen matched patient. In the context of EBV-LPD, the EBV-CTL find the cancer cells expressing EBV and kill them. Breakthrough therapy designation for EBV-CTL was based on data from two separate clinical trials of EBV-CTL conducted by MSK. Data from these studies have been submitted for presentation at an upcoming medical conference in 2015.

Enumeral Biomedical Holdings, Inc. and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology with Advanced Prototype System for Human Tissue Immuno-Oncology Profiling

Enumeral Biomedical Holdings, Inc. announced that the company signed an agreement with Memorial Sloan Kettering Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research contract with the National Cancer Institute. Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer. Enumeral’s Phase II program is focused on applying its human-driven immune profiling platform to small volume clinical specimens such as core biopsy or fine needle aspirates, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s human-driven immune profiling platform has the ability to determine cellular function in an unbiased fashion, allowing analysis of rare immune cells associated with disease or drug response in even the smallest clinical samples. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response, which may ultimately guide development of more precisely targeted immunotherapies. Enumeral’s collaboration with MSK is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral demonstrated proof of concept in this area under a Phase I contract in 2012 and 2013.

IBM Research Scientists Investigate Use of Cognitive Computing-Based Visual Analytics for Skin Cancer Image Analysis with Memorial Sloan Kettering

IBM announced a collaboration with Memorial Sloan Kettering to research the application of cognitive computing to analyze dermatological images of skin lesions with the goal of assisting clinicians in the identification of various cancerous disease states. The technology, which learns by identifying specific patterns in medical images, has the potential to increase the number of cases detected and help clinicians make earlier diagnoses. The automated analysis of skin imaging is one area of research that is currently being investigated by IBM Research, in conjunction with a larger international effort being led by Memorial Sloan Kettering.

Similar Private Companies By Industry

Company Name Region
AMERIGROUP Community Care of New Mexico, Inc. United States
Danville Regional Medical Center, LLC United States
NRFC Clinton Holdings, LLC United States
CIGNA HealthCare - Centennial State, Inc. United States
Ascend Healthcare, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Memorial Sloan Kettering Cancer Center, please visit www.mskcc.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.